Related Experiment Video
Updated: Jun 28, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Current state of anti-tumor necrosis factor therapy in autoimmune diseases]
Daniel Sánchez Cano1, José Luis Callejas Rubio, Norberto Ortego Centeno
1Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, Granada, Spain. danifilax@gmail.com
Abstract:
Tumor necrosis factor (TNF) alpha plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept and adalimumab) represents an important tool for the management of a variety of disorders, such as rheumatoid arthritis, the spondyloarthropathies, inflammatory bowel disease and psoriasis. Nonetheless, theoretically, some other autoimmune and inflammatory disorders may benefit from these agents. We intend to update on these off-label uses of anti-TNF blockers in this review.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)